Last Updated on
July 26, 2022
By
Excedr
DCVC is a venture capital firm that works with entrepreneurs solving trillion-dollar problems using Deep Tech.
Today, the world faces hundreds of challenges ranging from unsustainable global manufacturing and untreated medical diseases to global food crises. DCVC is focused on solving these issues by partnering with innovative scientific and business minds and building a sustainable and effective approach to creating a better world.
For over 20 years, the company has invested in transformational industry giants in a variety of areas, ranging from robotics, pharmaceutical, and healthcare, to life sciences, and has generated billions of dollars in backing startups with transformational ideas. It supports companies from their earliest phases to shape their ideas into reality, elevate their market reach, and turn them into valued and reputed companies.
DCVC was co-founded by Matthew Ocko and Zachary Bogue in 2011. It is currently headquartered in Palo Alto, California. The co-founders are now joined in leadership by two other managing partners: Dr. John Hamer and Dr. Kiersten Stead. Previously, the company invested in synthetic biology, biotech, and the life sciences. In 2020, it raised a $350M fund for its Deep Tech-enabled life sciences companies.
In this article, we will review DCVC’s portfolio companies its expert team, and its interest in “DeepTech”.
DCVC invests in a spectrum of startups working in a variety of areas, ranging from building robots and rockets to molecular manufacturing™ and automation platforms.
DCVC’s portfolio companies are categorized based on their areas, which include:
A few examples of the portfolio companies included in this category are:
DCVC’s investments in computational biology include companies like:
A few examples of DCVC’s investments in foundational technology include:
DCVC has invested in a range of startups involved in industrial transformation, some of which are:
DCVC has invested in a number of companies related to smart agriculture, including:
Some portfolio companies in this area are:
The DCVC team consists of experts from many areas, including technical, scientific, investment, and operational areas. Below are the names of the managing partners and leaders of the DCVC firm.
Zachary Bogue is a co-managing partner and co-founder of the DCVC firm. He holds 20 years of experience in different roles, ranging from an entrepreneur, advisor, attorney, venture capitalist, and angel investor.
Zack’s investment interests are mostly in building next-generation space informatics and robotics platforms, such as Planet Labs and Recursion Pharmaceuticals.
Matt Ocko is a co-founder and co-managing partner at the DCVC venture firm. In the company, he lookout to support startups in the areas of computational drug discovery and synthetic biology, anti-terror systems, and geospatial and space access platform.
Dr. John Hamer is a managing partner at DCVC Bio. Prior to joining DCVC, he worked at Monsanto as a Vice President and Director of Monsanto Growth Ventures (MGV).
Dr. Kiersten Stead is a managing partner at the DCVC venture capital firm, where she is focused on investing in life science companies, such as those working in the areas of agriculture, synthetic biology, and therapeutics.
Deep Tech is a term used for technologies that are based on advanced science and high-tech innovation and engineering, such as robotics, artificial intelligence (AI), biotech and quantum computing, and blockchain.
DCVC’s investment interests are rooted in Deep Tech, supporting startups that use highly-advanced technologies to develop and drive the solution to the world’s most challenging problems, such as life-threatening diseases, crop loss, climate change, and pollution.
Some of its portfolio companies that have had a major impact on the world include Pivot Bio, Zymergen, Recursion Pharma, and Planet Labs.
For more information on the DCVC firm and its portfolio companies, visit www.dcvc.com.
DCVC is a venture capital firm with investment interest in computational biology, geospatial, artificial intelligence, risk transformation, cybersecurity, and smart agriculture companies.
The firm looks for companies that apply Deep Tech, such as AI, robotics, and biotechnology to create disruptive solutions for the world’s most pressing issues, such as diseases with unmet medical demands, unpredictable weather changes leading to crop loss, and energy conservation and environmental pollution.
However, implementing such sciences requires advanced, cutting-edge equipment, making it difficult for cash-strapped startups to generate the data needed to capture the attention of firms like DCVC that can provide the funding necessary to build Deep Tech-enabled solutions.
Excedr provides biotech and life science startups with lab equipment leases, a cost-effective alternative to purchasing equipment with cash or a limited line of credit.
Our leasing program can be tailored to meet your lab’s needs, and allows you to outfit your entire lab with advanced equipment on lease. You can avoid the stress and difficulty of paying huge upfront costs or paying out of pocket for equipment repairs and maintenance when you use our leasing program.
Some of the equipment we lease includes imaging equipment, analytical equipment, clinical tools, and a wide range of life sciences and biotech equipment.
By saving money on equipment procurement, you leave yourself more room in your operational expenditure budget, extend your cash runway, and show venture capital firms you’re nimble and unimpeded by numerous fixed assets.
